WT but not Il33−/− mADSCs suppress inflamed tissue damage and improve submandibular gland function in NOD/ShiLtj mice
(A) Salivary flow rate of NOD/ShiLtj treated with PBS, ADSC from WT or Il33−/− mice. PBS group (n = 12), KO group (n = 12), WT group (n = 12). (B) Slc12a2 mRNA expression in the submandibular glands of NOD/ShiLtj mice injected with PBS, ADSC from WT or Il33−/− mice.
(C) Tjp1 mRNA expression in the submandibular glands of NOD/ShiLtj mice injected with PBS, ADSC from WT or Il33−/− mice.
(D) Itpr3 mRNA expression in the submandibular glands of NOD/ShiLtj mice injected with PBS, ADSC from WT or Il33−/− mice.
(E) Trpv4 mRNA expression in the submandibular glands of NOD/ShiLtj mice injected with PBS, ADSC from WT or Il33−/− mice.
(F) Chrm3 mRNA expression in the submandibular glands of NOD/ShiLtj mice injected with PBS, ADSC from WT or Il33−/− mice.
(G) Aqp5 mRNA expression in the submandibular glands of NOD/ShiLtj mice injected with PBS, ADSC from WT or Il33−/− mice.
(H) Histology of the submandibular glands of NOD/ShiLtj mice injected with PBS, ADSC from WT or Il33−/− mice.
(I) The infiltrating area in the submandibular glands of NOD/ShiLtj mice injected with PBS, ADSC from WT or Il33−/− mice. Data are pooled from three independent experiments. One-way ANOVA was used. Scale bars, 100 μm and 50 μm; bars, mean; error bars, SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.